Aflibercept's Mechanism in VEGFR Inhibition

How does aflibercept inhibit VEGF receptor (VEGFR-1/VEGFR-2) activation in retinal disease?

Aflibercept inhibits VEGFR-1 and VEGFR-2 activation in retinal disease by binding VEGF-A, VEGF-B, and PlGF with subpicomolar to picomolar affinity, forming 1:1 complexes that sequester these ligands and prevent their engagement with cognate receptors.

Abstract

Aflibercept inhibits VEGFR-1 and VEGFR-2 activation primarily through high-affinity sequestration of VEGF family ligands, binding VEGF-A with subpicomolar affinity (KD = 0.490 pM) and blocking receptor activation with IC50 values of 15-26 pM.

Unlike antibody-based therapies, aflibercept forms a 1:1 complex with VEGF dimers and uniquely occludes both the receptor-binding sites and heparin-binding site on VEGF165, preventing receptor engagement while exhibiting faster association rates than bevacizumab or ranibizumab.

Methods

We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 6 key aspects relevant to the research question.

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

The search returned 200 total results.

Screening

Papers screened based on their abstracts met the following criteria:

• Retinal Disease Population: Involvement of patients with retinal diseases.
• Aflibercept Intervention: Investigation of aflibercept as the primary intervention.
• VEGF Receptor Mechanisms: Examination of VEGF receptor activation or inhibition.
• Mechanistic Assessments: Inclusion of molecular or pharmacological assessments of VEGF pathway modulation.
• Study Design and Sample Size: Randomized controlled trial or observational study with original mechanistic data.
• Mechanistic Data Inclusion: Inclusion of mechanistic data on VEGF receptor inhibition.
• Aflibercept-Specific Effects: Ability to distinguish aflibercept's individual drug effects from combination therapies.

Target Binding Properties

Aflibercept demonstrated distinct binding characteristics across VEGF family ligands:

• Specific ligands bound: All isoforms of human VEGF-A, PlGF-2, VEGF-B.
• Binding affinity for VEGF-A: KD = 0.490 pM.
• Association rate: Faster than that of bevacizumab and ranibizumab.
• Binding stoichiometry: 1:1 with VEGF dimers.

VEGFR Inhibition Mechanisms

Direct Receptor Inhibition

Aflibercept inhibited both VEGFR1 and VEGFR2 activation through high-affinity ligand sequestration. For VEGF-A121, aflibercept blocked VEGFR1 activation with IC50 = 15 pM and VEGFR2 activation with IC50 = 16 pM.

Downstream Signaling Effects

Aflibercept inhibited VEGF-A-induced calcium mobilization and cell migration more potently than other therapies. It restored and prevented VEGF-A-induced disturbance of retinal endothelial barrier function.

Effects on Retinal Cell Types

• Retinal endothelial cells: Reduced migration and calcium mobilization; inhibited proliferation.
• Retinal pericytes: Prevented glucose-induced damage; improved viability.
• Retinal pigment epithelium (RPE) cells: Downregulated PEDF; increased viability and migration.
• Mononuclear phagocytes: Reduced numbers of activated MPs in choroidal neovascularization.

Functional Outcomes Across Retinal Disease Models

PDR (human tissue)

• Suppressed galectin-1-stimulated VEGFR2 activation.

Diabetic macular edema (cell culture)

• Restored barrier function.

Neovascular AMD (human trials)

• Improved visual acuity.

Comparative Mechanistic Analysis

Aflibercept showed greater inhibitory effects compared to ranibizumab and bevacizumab in several parameters, including binding affinity and suppression of angiogenesis.

Synthesis: Canonical and Non-Canonical Mechanisms

Aflibercept operates through both direct VEGFR inhibition and non-canonical mechanisms, including binding galectin-1 and PDGFRα, altering the effects of hypoxia-inducible factor-1α.

References

• Kanda et al., 2015. Aflibercept Traps Galectin-1, an Angiogenic Factor Associated with Diabetic Retinopathy. Scientific Reports
• MacDonald et al., 2016. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab. Angiogenesis.
• Pennock et al., 2014. Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor α to promote proliferative vitreoretinopathy.